OpenAI In Talks With Broadcom To Develop New AI Chip, Aims To Reduce Reliance On Nvidia: Report
OpenAI is in discussions with Broadcom Inc. (NASDAQ:AVGO) to co-develop a new AI chip. This move is aimed at reducing the company's dependency on Nvidia Corp. (NASDAQ:NVDA) and strengthening its
$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much Today
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 12.43% on an annualized basis producing an average annual return of 20.85%. Currently, Illumina has a market
SA Interview: Apex Trader Funding Talks Stocks, Biden-Trump, Why Cash Is a Good Position
(WSO) - Analyzing Watsco's Short Interest
Watsco's (NYSE:WSO) short percent of float has fallen 11.68% since its last report. The company recently reported that it has 3.07 million shares sold short, which is 10.06% of all regular shares
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past 20 years by 6.44% on an annualized basis producing an average annual return of 14.87%. Currently, Biomarin
Nvidia, Electronic Arts And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by around 600 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.When insiders sell shares, it could be a preplanned sale, or could
$1000 Invested In This Stock 15 Years Ago Would Be Worth $18,000 Today
EMCOR Group (NYSE:EME) has outperformed the market over the past 15 years by 8.43% on an annualized basis producing an average annual return of 20.74%. Currently, EMCOR Group has a market
Here's How Much You Would Have Made Owning Reliance Stock In The Last 20 Years
Reliance (NYSE:RS) has outperformed the market over the past 20 years by 6.45% on an annualized basis producing an average annual return of 14.98%. Currently, Reliance has a market capitalization of $
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past 20 years by 6.65% on an annualized basis producing an average annual return of 15.22%. Currently, Biomarin
NIH Outlays Rise by 5% in June, Says Baird
10 Consumer Discretionary Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Retail Sales Breakdown: Clothes and AI Laptops Are Winning Out Over Furniture and Home Improvement
Peering Into Lennox Intl's Recent Short Interest
Lennox Intl's (NYSE:LII) short percent of float has fallen 8.72% since its last report. The company recently reported that it has 886 thousand shares sold short, which is 3.14% of all regular shares
TD Cowen Maintains Buy on Williams-Sonoma, Adjusts Price Target To $170 (2-1 Stock Split)
TD Cowen analyst Max Rakhlenko maintains Williams-Sonoma (NYSE:WSM) with a Buy, adjusts target to $170 from $340 (2-1 Stock Split).
Carlisle Companies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 16.12% Baird $465 → $500 Maintains Outperform 04/26/2024 -0.14% Oppenheimer $412 → $430
Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 12.7% on an annualized basis producing an average annual return of 21.1%. Currently, Illumina has a market capitalization
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Lowers Price Target to $170
Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:WSM) with a Outperform and lowers the price target from $340 to $170.
Williams-Sonoma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 11.07% Telsey Advisory Group $340 → $170 Maintains Outperform 06/07/2024 96.01% RBC Capital $30
Dividend Roundup: Procter & Gamble, Costco, CVS Health, Colgate-Palmolive, and More